We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Serina Therapeutics Inc (SER) USD0.0001

Sell:$5.25 Buy:$15.66 Change: $0.12 (1.20%)
Market closed |  Prices as at close on 21 May 2024 | Switch to live prices |
Sell:$5.25
Buy:$15.66
Change: $0.12 (1.20%)
Market closed |  Prices as at close on 21 May 2024 | Switch to live prices |
Sell:$5.25
Buy:$15.66
Change: $0.12 (1.20%)
Market closed |  Prices as at close on 21 May 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Serina Therapeutics, Inc., formerly AgeX Therapeutics, Inc., is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of wholly owned drug product candidates to treat neurological diseases and pain. Its POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. Its POZ Platform partners are at the forefront in advancing LNP delivery technology to develop RNA therapeutics. The Company is focused on the advancement of its lead drug candidate, SER-252 (POZ-apomorphine), for the treatment of advanced Parkinson’s Disease through pre-clinical studies. The Company intends to advance SER 252 into Phase I clinical trials.

Contact details

Address:
1101 MARINA VILLAGE PARKWAY, SUITE 201
ALAMEDA
94501
United States
Telephone:
+1 (510) 6718370
Website:
https://www.agexinc.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
SER
ISIN:
US81751A1088
Market cap:
$84.14 million
Shares in issue:
8.41 million
Sector:
Biotechnology
Exchange:
-
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Simba Gill
    Executive Chairman of the Board
  • Steven Ledger
    Interim Chief Executive Officer, Director
  • Andrea Park
    Interim Chief Financial Officer, Chief Accounting Officer
  • Tacey Viegas
    Chief Operating Officer, Company Secretary
  • Randall Moreadith
    Chief Scientific Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.